Enable Accessibility Enable Accessibility

Responsible Innovation: R&D to Address Unmet Medical Needs

Patient-ResponsibleInnovation

Research and development (R&D) is fundamental to our culture and an element of our strategic roadmap that drives innovation at Takeda. For almost 240 years, we’ve focused on delivering Better health for people, brighter future for the world, setting and adhering to a high bar for innovation, sourcing innovation through partnerships and managing the pipeline dynamically through key data readouts, especially to address critical unmet patient needs.

Within Innovative Biopharma, the largest component of our R&D investment, we focus on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience and Gastroenterology. In these areas, we’re focused on targeted patient populations where we’re able to deliver the greatest therapeutic benefit for patients. To fuel our R&D engine, we seek the best possible science, internally or externally, and invest for the long term. Takeda R&D is modality agnostic, and we innovate through a strong internal laboratory that also draws on expertise from our robust network of partnerships. Together with our partners, our goal is to discover, develop and deliver medicines with transformative or curative potential.

Our pipeline is projected to deliver value in two distinct waves. In the near term through FY2024, we are progressing 12 new molecular entities (NMEs) representing best-in-class or first-in-class therapies. This includes two exciting programs — TAK-007 and TAK-994. TAK-007 is a Phase 1/2 CD19-targeted chimeric antigen receptor-directed natural killer (CAR-NK) cell therapy with potential for off-the-shelf use in hematologic malignancies. TAK-994, part of our orexin 2 receptor agonist franchise, is a first-in-class oral small molecule that addresses the underlying orexin deficiency of narcolepsy type 1 patients aiming to restore normal function.

Looking to FY2025 and beyond, our R&D engine with internal research capabilities and external partnerships is expected to deliver a steady stream of next-generation therapies that will sustain our growth. These programs leverage new platform capabilities in cell therapy, gene therapy and data sciences.

We innovate along the asset life cycles — from target identification through clinical development and commercialization. Rather than engaging in strict licensing agreements and traditional acquisitions, we enter into mutually beneficial partnerships with biotech and pharmaceutical organizations, academic institutions and nonprofit and government organizations who are like-minded and focused on advancing innovation.

We understand the importance of building R&D capacity, as well as scientific and technical expertise, in low- and middle-income countries (LMICs) to create sustainable health research and delivery systems. No one is better placed to solve local challenges faced by societies than the medical professionals and researchers who live there and have a vested interest in solving the problems impacting the population. Accordingly, we’re taking an innovative and industry-leading approach to strengthen health care capacity in LMICs through knowledge-sharing collaborations with nonprofit partners and local health care teams. These programs complement the partnerships we have in our Access to Medicines programs and help strengthen health care systems overall in underserved countries.

Patient-ResponsibleInnovation_2
Patient-ResponsibleInnovation-3

"We believe that no one is better placed to solve local challenges faced by societies than the medical professionals and researchers who live there and have a vested interest in solving the problems impacting the population — and we work closely with them locally."